U.S. Esoteric Testing Market Size, Share & COVID-19 Impact Analysis, By Technology (Enzyme-linked Immunosorbent Assay, Chemiluminescence Immunoassay, Mass Spectrometry, Flow Cytometry, Polymerase Chain Reaction, and Others), By Test Type (Infectious Disease Testing, Endocrinology Testing, Oncology Testing, Toxicology Testing, and Others), By End-user (Hospital-based Labs, and Independent and Referral Labs), and Country Forecast, 2023-2030

The U.S. esoteric testing market size was worth USD 9.08 billion in 2022 and is projected to grow at a CAGR of 11.0% during the forecast period. 

Esoteric testing refers to specialized diagnostic procedures performed in laboratories to detect rare or complex medical conditions that are not typically covered by routine tests. The U.S. has witnessed the growing prevalence of rare diseases, which has increased the large number of cases of diagnosis of these diseases, which is anticipated to increase the demand for this type of testing.

The market is propelled by several factors, including advancements in medical technology and genomic research and the demand for more precise and targeted treatment approaches. Additionally, the expanding aging population and rising awareness among healthcare professionals about the benefits of esoteric testing contribute to the market's growth.

In 2020, during the COVID-19 pandemic, the market experienced positive growth in the U.S. The positive growth is attributed to the growing number of patient visits to hospitals and clinics for COVID-19 tests. In 2021 and 2022, the market was normalized and was reverted back to the pre-pandemic era due to the initiation of vaccination for the COVID-19 and reduction in the COVID-19 test. Additionally, the resumption of healthcare facilities for the diagnosis of other chronic diseases was one of the other factors that contributed to the market normalization in 2022.  

U.S. Esoteric Testing Market Trends

Technological Advancements in Testing to Fuel Market Growth

Technological advancements in esoteric testing are a significant and ongoing market trend that has been increasing the adoption of this testing in the market. The growing demand for technologies, such as Next-Generation Sequencing (NGS) and mass spectrometry, has led to precision, speed, and accessibility of esoteric testing, ultimately leading to better patient care and is anticipated to drive the U.S. esoteric testing market growth. Furthermore, it has been seen that various laboratories have increased their focus on such technologies in testing to provide better services.

U.S. Esoteric Testing Market Growth Factors

Growing Burden of Rare Diseases to Augment Market Growth

The rising prevalence of complex and rare diseases is driving market growth. These advanced tests are becoming essential in identifying complex or rare medical conditions, guiding healthcare professionals toward more precise and effective treatment strategies, and ultimately enhancing patient outcomes.

• For instance, according to the data published by NORD in June 2020, there are more than 7,000 rare diseases affecting more than 30 million Americans.

Moreover, the growing awareness of rare diseases and the need for personalized medicine further fuel the adoption of esoteric testing.  Moreover, the expanding application of this testing in various medical specialties, including oncology, genetics, and infectious diseases, contributes to a broader awareness of its utility.

RESTRAINING FACTORS

High Costs of Diagnostic Procedures to Hinder Market Growth

The high prices of esoteric testing procedures present a barrier to the growth of the esoteric testing market in the U.S. The costliness of these specialized tests can strain healthcare budgets, limit patient access, and deter healthcare providers from ordering them, especially when more affordable options are available. Insurance coverage limitations and out-of-pocket expenses for patients also contribute to this challenge.

In the U.S., the estimated cases of breast cancer and kidney & renal pelvis cancer were 290,560 and 79,000 in 2022.

U.S. Esoteric Testing Market Segmentation Analysis

By Technology Analysis

Based on technology, the U.S. esoteric testing market is segmented into enzyme-linked immunosorbent assay, chemiluminescence immunoassay, mass spectrometry, flow cytometry, polymerase chain reaction, and others.

The chemiluminescence immunoassay segment held the largest U.S. esoteric testing market share in 2022 due to the increasing prevalence of chronic diseases and the growing focus of market players in the development of innovative medical devices that have this technology.

• For instance, in May 2021, Inova Diagnostics' received emergency permission from the U.S. FDA for QUANTA Flash SARSCoV2 IgG. It is used in the BIOFLASH Random Access Chemiluminescent Analyzer.

The mass spectrometry segment held the substantial market share in 2022. The segmental growth is due to its high sensitivity, accuracy, and versatility in analyzing complex biomolecules. Furthermore, increasing demand for advanced diagnostic technologies, expanding applications in clinical research, and rising prevalence of chronic diseases is expected to propel the segmental growth.

By Test Type Analysis

Based on the test type, the market is segmented into infectious disease testing, endocrinology testing, oncology testing, toxicology testing, and others.

The infectious disease testing segment held the highest share in 2022 and is projected to grow at a substantial CAGR during the forecast period. The growth of the segment is attributed to the growing number of patient visits to physician offices for the diagnosis of these diseases, coupled with the growing prevalence of infectious diseases in the country.

• For instance, according to the CDC, in the U.S., the number of visits to physician offices for infectious and parasitic diseases was 10.2 million in 2019.

Oncology testing segment is expected to grow at the notable CAGR during the forecast period. The growth is due to the advancements in precision medicine, increasing cancer incidence rates, and the emerging demand for personalized treatment options.

By End-user Analysis

Based on end-user, the U.S. esoteric testing market is segmented into hospital-based labs and independent and referral labs.

The independent and referral labs segment is anticipated to grow at the highest CAGR during the forecast period. The growth is due to their specialized expertise and flexibility in offering a diverse range of advanced esoteric tests. These labs offer efficient and customizable testing solutions, thereby meeting the increasing demand for esoteric diagnostics in various medical specialties.

In 2022, the hospital-based labs segment accounted for a significant share of the market in 2022. The segmental growth is attributed to the growing demand for comprehensive diagnostic services within hospital-based labs.

List of Key Companies in U.S. Esoteric Testing Market

In terms of the competitive landscape, the market depicts the presence of companies operating in the market. Leading market players, such as Quest Diagnostics Incorporated and Laboratory Corporation of America, held a significant market share. Quest Diagnostics Incorporated is one of the prominent companies due to its strong direct and indirect presence and broad test portfolio in the market.

Some other companies with a considerable presence in the U.S., such as Eurofins Scientific, ACM Global Laboratories, and other small & medium-sized players. These companies are focusing on strengthening their portfolio to propel their share in the market.

LIST OF KEY COMPANIES PROFILED:

• Eurofins Scientific (U.S.)


• Quest Diagnostics Incorporated (U.S)


• Laboratory Corporation of America (U.S.)


• ACM Global Laboratories (U.S.)


• Mayo Foundation (U.S.)


• ARUP Laboratories (U.S.)


• OPKO Health, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• September 2022 - Neogen Corporation introduced the Veratox VIP assay to detect cashew allergy. The assay is the second assay in Neogen's new Veratox VIP line of ELISA products.


• March 2022 - Waters Corporation announced the launch of the Xevo TQ Absolute system, a compact benchtop and highly sensitive tandem mass spectrometer.


• February 2021 - Quest Diagnostics and GRAIL, Inc. collaborated to provide phlebotomy services to support Galleri, GRAIL’s multi-cancer early detection blood test.

REPORT COVERAGE

The U.S. esoteric testing market analysis provides detailed information of the market. It focuses on key aspects, such as the prevalence of key diseases in the country. Additionally, it includes an overview of market segments, key industry developments and product launches in the market. Additionally, it encompasses the impact of COVID-19 and the industry overview during the pandemic is covered in the report.

Report Scope & Segmentation